Page last updated: 2024-12-07
norfloxacin nicotinate
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
norfloxacin nicotinate: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 83908 |
| SCHEMBL ID | 4864800 |
| MeSH ID | M0237564 |
Synonyms (28)
| Synonym |
|---|
| norfloxacin nicotinate |
| 3-quinolinecarboxylic acid, 1-ethyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-, mono-3-pyridinecarboxylate |
| 3-quinolinecarboxylic acid, 1,4-dihydro-1-ethyl-6-fluoro-4-oxo-7-(1-piperazinyl)-, mono-3-pyridinecarboxylate |
| D08287 |
| quinabic soluble powder (tn) [veterinary] |
| 118803-81-9 |
| c22h23fn4o5 |
| FT-0631092 |
| 1-ethyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid compound with nicotinic acid (1:1) |
| SCHEMBL4864800 |
| nicotinic acid norfloxacin |
| WRIFLTAYLRDENF-UHFFFAOYSA-N |
| DTXSID10152246 |
| J-003889 |
| AKOS027322041 |
| E76213 |
| mfcd00873666 |
| 1-ethyl-6-fluoro-4-oxo-7-piperazin-1-ylquinoline-3-carboxylic acid;pyridine-3-carboxylic acid |
| DS-11847 |
| BCP13348 |
| 1-ethyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid nicotinic acid salt |
| A910803 |
| 1-ethyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-3-quinolinecarboxylic acid nicotinate |
| CS-0144754 |
| norfloxacin (nicotinate) |
| 1-ethyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylicacidcompoundwithnicotinicacid(1:1) |
| HY-B0132B |
| 1-ethyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid; pyridine-3-carboxylic acid |
Research Excerpts
Overview
Norfloxacin nicotinate (NFN) is a new water-soluble fluoroquinolone antibacterial agent.
| Excerpt | Reference | Relevance |
|---|---|---|
| "Norfloxacin nicotinate (NFN) is a new water-soluble fluoroquinolone antibacterial agent. " | ( Clinical pharmacokinetic characterization of norfloxacin nicotinate in swine following systemic administration. Shem-Tov, M; Ziv, G, 1994) | 1.99 |
Toxicity
| Excerpt | Reference | Relevance |
|---|---|---|
| " Nowadays, increasing evidences showed that NOR could pose toxic effects on fish and other aquatic organisms, but as its adduct, whether NOR-N could cause adverse effects on aquatic organisms is still unclear." | ( Effects of norfloxacin nicotinate on the early life stage of zebrafish (Danio rerio): Developmental toxicity, oxidative stress and immunotoxicity. Fang, H; Li, K; Liang, X; Nie, X; Wang, F, 2020) | 0.95 |
Pharmacokinetics
| Excerpt | Reference | Relevance |
|---|---|---|
| " The in vitro activity of NFN for microorganisms isolated from swine and the pharmacokinetic properties of NFN following single intravenous (i." | ( Clinical pharmacokinetic characterization of norfloxacin nicotinate in swine following systemic administration. Shem-Tov, M; Ziv, G, 1994) | 0.55 |
| " However, a significant difference was observed in clearance, mean residence time and the half-life values between the unweaned and weaned calves." | ( Norfloxacin nicotinate pharmacokinetics in unweaned and weaned calves. Gips, M; Soback, S, 1996) | 1.74 |
| " The pharmacokinetic parameters of common carp were similar to those of crucian carp." | ( Comparative pharmacokinetics of norfloxacin nicotinate in common carp (Cyprinus carpio) and crucian carp (Carassius auratus) after oral administration. Ai, X; Liu, Y; Xu, N; Yang, Q, 2015) | 0.7 |
Bioavailability
| Excerpt | Reference | Relevance |
|---|---|---|
| " Oral bioavailability was rather poor (9." | ( Intravenous disposition kinetics, oral and intramuscular bioavailability and urinary excretion of norfloxacin nicotinate in donkeys. Glickman, A; Lavy, E; Ziv, G, 1995) | 0.51 |
| " Bioavailability was 51-64%." | ( Clinical pharmacokinetic characterization of norfloxacin nicotinate in swine following systemic administration. Shem-Tov, M; Ziv, G, 1994) | 0.55 |
| " The absorption rate after intramuscular administration appeared to change as a result of dose increase." | ( Norfloxacin nicotinate pharmacokinetics in unweaned and weaned calves. Gips, M; Soback, S, 1996) | 1.74 |
Dosage Studied
| Excerpt | Relevance | Reference |
|---|---|---|
| " After multiple dosing some local swelling was observed at the injection site." | ( Intravenous disposition kinetics, oral and intramuscular bioavailability and urinary excretion of norfloxacin nicotinate in donkeys. Glickman, A; Lavy, E; Ziv, G, 1995) | 0.51 |
| " dosing best fitted a 2-compartment open system pharmacokinetic model." | ( Clinical pharmacokinetic characterization of norfloxacin nicotinate in swine following systemic administration. Shem-Tov, M; Ziv, G, 1994) | 0.55 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Research
Studies (9)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 7 (77.78) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (11.11) | 24.3611 |
| 2020's | 1 (11.11) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 25.81
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (25.81) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 1 (11.11%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 1 (11.11%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 7 (77.78%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||